Short answer
Neurogene Inc. (NGNE) filed its Q1 2026 10-Q quarterly report on May 12, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$31M
- −36.6% YoY
- EPS (diluted)
- −$1.39
- −28.7% YoY
Source: XBRL data from the Neurogene Inc. (NGNE) Q1 2026 10-Q on SEC EDGAR. USD.
Neurogene Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, no commercial product sales; unchanged from $0 in Q1 2025
- Net loss $30.9M vs $22.6M YoY
- Cash, equivalents and short-term investments $243.2M at March 31, 2026
- Embolden approximately 90% dosed; completion targeted Q2 2026
- Mid-2026 data expected; PPQ campaign planned, with macroeconomic and supply-chain headwinds
Risk Factors
- NGN-101 advancement risk: FDA denied RMAT designation, eliminating the streamlined registrational pathway and threatening program discontinuation
- NGN-401 concentration risk: Embolden registrational trial remains central after dosing began in fourth quarter 2025
- Regulatory risk: Gene-therapy approval requirements remain rigorous, complex, uncertain and subject to change
- Liquidity risk: Cash, cash equivalents and short-term investments expected to fund operations through first quarter 2028
- Financing risk: $119.0 million remains available under the ATM after $31.0 million in shares sold by March 31, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Neurogene Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.